Checkpoint inhibition

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
Hanne Lind, Sofia R Gameiro, Caroline Jochems, Renee N. Donahue, Julius Strauss, James L Gulley, Claudia Palena, Jeffrey Schlom

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000433; DOI: 10.1136/jitc-2019-000433
Dual checkpoint inhibitor-associated eosinophilic enteritis
J. Yang, S. M. Lagana, Y. M. Saenger, R. D. Carvajal

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 310; DOI: 10.1186/s40425-019-0743-5
A new paradigm for tumor immune escape: β-catenin-driven immune exclusion
Stefani Spranger, Thomas F. Gajewski

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (1) 43; DOI: 10.1186/s40425-015-0089-6
Targetless T cells in cancer immunotherapy
Per thor Straten, Federico Garrido

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 23; DOI: 10.1186/s40425-016-0127-z
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
Patrick Danaher, Sarah Warren, Rongze Lu, Josue Samayoa, Amy Sullivan, Irena Pekker, Brett Wallden, Francesco M. Marincola, Alessandra Cesano

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 63; DOI: 10.1186/s40425-018-0367-1
Immuno-thermal ablations – boosting the anticancer immune response
Ryan Slovak, Johannes M. Ludwig, Scott N. Gettinger, Roy S. Herbst, Hyun S. Kim

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 78; DOI: 10.1186/s40425-017-0284-8
Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model
Zachary S Morris, Emily I Guy, David M Francis, Monica M Gressett, Eric A Armstrong, Shyhmin Huang, Stephen D Gillies, Alan J Korman, Jacquelyn A Hank, Alexander L Rakhmilevich, Paul M Harari, Paul M Sondel

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P308; DOI: 10.1186/2051-1426-3-S2-P308
A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)
Robert L Ferris, Benjamin A Kansy, Sandra Poveda Gibson, Raghvendra M Srivastava, James Kyle Bryan, Robert M Hershberg

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P144; DOI: 10.1186/2051-1426-3-S2-P144
Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma
Morganna Freeman, Jeffrey Weber

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P133; DOI: 10.1186/2051-1426-3-S2-P133
Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 mouse melanoma
Xianming Huang, Jian Gong, Dan Ye, Van Nguyen, Shen Yin, Rich Archer, Chris Hughes, Rolf Brekken, Jeff Hutchins, Alan Schroit, Bruce Freimark

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P205; DOI: 10.1186/2051-1426-2-S3-P205

Main menu

Checkpoint inhibition

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Checkpoint inhibition

Pages